EORTC-Studien: Lungentumoren
| zurück | EORTC-Studien: Lungentumoren | ||
| Allgemeines | |||
| 22923 | ARCON | ||
| 08974 | NSCLC | ||
| 08941 | NSCLC | ||
| 08912 | SCLC | ||
| 08031 | Mesotheliom | Induktions - Chemotherapie, dann extrapleurale Pneumonektomie, dann postoperative Radiotherapie | |
| 08 09 2 | Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. | ||
| 08 07 2 | Concurrent once-daily versus twice-daily radiotherapy : A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status | ||
| 08 06 2 | Randomization phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC (ES). | ||
| 08 06 1 | Phase II study of sunitinib (SU11248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a "sensitive" relapse. | ||
| 22 05 5 | Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement - LUNG-ART | ||
| 22 05 5C | Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement | ||
| 08 05 1 | Randomized Phase II Study Of Pemetrexed And Cisplatin As Either Induction or Adjuvant Chemotherapy In Stage IB-II Non-Small Cell Lung Cancer (NSCLC) | ||
| 08 03 1 | Mesotheliom | Induktions - Chemotherapie, dann extrapleurale Pneumonektomie, dann postoperative Radiotherapie | |
| 08 02 1 | A randomized phase III study of follow up with or without adjuvant Gefitinib (Iressa TM) following chemotherapy in patients with advanced Non-Small Cell Lung Cancer. | ||
| 08 01 3 | Phase II study with Gefitinib (sequentially) following Gemcitabine/Cisplatin as induction regimen for patients with stage IIIA N2 NSCLC | ||
| 08 01 2 | Pre-operative chemotherapy in resectable NSCLC. Randomised trial of surgical resection with or without pre-operative chemotherapy in patients with operable non small cell lung cancer (NSCLC) of any stage. | ||
| 22 00 3 | A multicenter randomised trial of high versus standard doses of prophylactic cranial irradiation in limited small cell lung cancer complete responders. (An intergroup study with the PCI99-EULINT Collaborative Group, the EORTC Radiotherapy Group and the EORTC Lung Cancer Group.) | ||
| 22 99 4 | A Phase I Study on the Feasibility of High Dose Three-Dimensional Conformal Radiotherapy in Patients with Inoperable and Locally Advanced Non Small Cell Lung Cancer. | ||
| 22 99 3 | EORTC Study 22993-08993 Prophylactic cranial irradiation in extensive disease small cell lung cancer. (A joint study with the EORTC Radiotherapy and Lung Cancer Groups) | ||
| 16 99 6SL | Open label phase II study on RFS 2000 (9-nitro-camptothecin,9NC) administered as a "5days on-2days off"oral treatment in advanced small cell lung cancer eortc study 16996SL | ||
| 16 99 1N | Open label Phase II study on XR5000 administered as a 5 day infusion in advanced non small cell lung cancer: EORTC study 16991N | ||
| 08 98 1 | Surgical treatment of stage IIIB non-small cell lung cancer after induction chemo-radiotherapy. | ||
| 08 98 4 | Taxotere and Cisplatin as induction chemotherapy in patients with stage IIIa N2 non small cell lung cancer (NSCLC) | ||
| 16 99 4N | Open label phase II study on Glufosfamide administered as a 60 minute infusion every 3 weeks in advanced non small cell lung cancer: EORTC study 16994N | ||
| 08 97 1b | Survival in an international phase III prospective randomized LD small cell lung cancer vaccination study with adjuvant BEC2 and BCG | ||
| 08 97 2 | Randomized phase III study comparing induction chemotherapy to daily low dose cisplatin both combined with high dose radiotherapy in patients with inoperable non-small cell lung cancer stage I, II and (low volume) stage III. | ||
| 08 97 5 | Randomised study with new combination chemotherapies in advanced non-small cell lung cancer. | ||
| 08 97 1 | Survival in an international phase III prospective randomized LD small cell lung cancer vaccination study with adjuvant BEC2 and BCG | ||
| 08 97 4 | NSCLC | ||
| 08 96 5 | Temozolomide in advanced non-small cell lung cancer with and without brain metastases: Phase II | ||
| 08 96 2 | A phase III study of Marimastat in patients with small cell lung cancer following a response to first line chemotherapy. | ||
| 08 95 6 | Phase II study on Taxol in bronchioalveolar carcinoma | ||
| 08 95 8 | Phase II study on Carboplatin and Taxol as induction regimen in stage IIIa (N2) non-small cell lung cancer (NSCLC) | ||
| 08 95 7 | Phase II study on Topotecan in combination with Cisplatin as second line treatment of small cell lung cancer | ||
| 08 96 1 | Phase II study of VIP (Etoposide, Ifosfamide and Cisplatin) in the treatment of invasive thymoma (In collaboration with ECOG, SWOG and CALGB) | ||
| 08 95 1 | Phase III trial on sequential radiotherapy with or without daily Cisplatin in patients with small cell lung cancer limited to chest and good response to induction chemotherapy | ||
| 08 95 5 | A phase II study of Gemcitabine and Cisplatin as induction regimen in stage IIIa non-small cell lung cancer. | ||
| 08 95 2 | Adjuvant chemotherapy in completely resected stage I, II, and IIIa non-small cell lung cancer. A prospective randomized Phase III inter-group study (In collaboration with the Adjuvant Lung Project Italy - ALPI) | ||
| 08 94 1 | NSCLC | Randomized trial of surgery versus radiotherapy in patients with stage IIIa non-small cell lung cancer after a response to induction-chemotherapy. | |
| 08 92 3 | A phase III study of standard CDE vs intensified CDE with G-CSF + prophylactic antibiotics in small cell lung cancer | ||
| 08 92 5 | A randomized trial of two Cisplatin-based combination chemotherapies in advanced non-small cell lung cancer. A phase II study leading to a phase III | ||
| 16 92 2S | Phase II trial with Topotecan in patients with small cell lung cancer (extensive disease) (In collaboration with the EORTC Lung Cancer Cooperative Group) | ||
| 16 92 1N | Phase II trial with Taxotere in patients with non-small cell lung cancer | ||
| 16 92 1S | Phase II trial with Taxotere in patients with small cell lung cancer (extensive disease) | ||
| 08 92 1 | UK02 EORTC/MRC/UKCCCR collaborative randomized phase III study of prophylactic cranial irradiation in patients with small cell lung cancer of limited extent who achieve a complete response to induction chemotherapy | ||
| 22 92 3 | ARCON | ||
| 16 90 2L | Phase II trial of Elsamitrucin (BMY 28090) in patients with non-small cell lung cancer | ||
| 08 91 2 | SCLC | ||
| 08 91 1 | Phase II trial of oral ifosfamide vs intravenous ifosfamide in advanced non small cell lung cancer | ||
| 08 90 2 | Phase II trial of suramin in advanced non small cell lung cancer | ||
| 08 89 1 | The role of radiotherapy in the treatment of brain metastases of small cell lung cancer. A phase II and phase III study | ||
| 08 90 1 | Etoposide in mesothelioma. A phase II study of cotinuous chemotherapy | ||
| 08 89 2 | Phase II trial of Navelbine (Vinorelbine) in pretreated patients with small cell carcinoma of the lung | ||
| 04 89 1 | Essais cliniques phase II d'une nouvelle nitrosourée: la Cystémustine dans les poumons, les adénocarcinomes colo-rectaux, les gliomes, les mélanomes, les reins, les sarcomes des parties molles et les tumeurs de la tête et du cou. | ||
| 16 89 2S | Phase II trial of 4'-iodo-4'-deoxydoxorubicin in patients with cell lung cancer | ||
| 16 89 2N | Phase II trial of 4'-iodo-4'-deoxydoxorubicin in patients with non-small cell lung cancer | ||
| 08 88 3 | Phase III trial on the evaluation of gamma Interferon for intensification/ maintenance of complete or near complete response in small cell lung cancer | ||
| 08 88 1 | A RANDOMIZED MULTI-CENTRE STUDY TO COMPARE THE EFFICACY AND TOLERABILITY OF ICS 205-930 WITH A METOCLOPRAMIDE-CONTAINING ANTIEMETIC COCKTAIL FOR THE PREVENTION OF CISPLATIN-INDUCED EMESIS. | ||
| 08 88 2 | Phase III trial of standard versus alternating chemotherapy in small cell lung cancer, extensive disease | ||
| 08 87 7 | Alternating versus sequential radio-chemotherapy in limited disease small cell lung cancer; a randomized phase III study | ||
| 08 87 1 | EUROSCAN: Phase III randomized study of chemoprevention with vitamin A and N-acetylcysteine in patients curatively treated for carcinomas of the larynx, oral cavity and lung (Jointly with the EORTC Head and Neck Cooperative Group : Protocol 24871) | ||
| 08 87 5 | Phase III randomized trial in metastatic non-small cell lung cancer | ||
| 07 87 1 | Phase III Randomized Comparison of Intensive Multidrug Chemotherapy with ADR/CTX/VP-16/CACP/DAVA/VCR/MTX with Leucovorin Rescue vs Standard AVE (ADR/VP-16/CTX) in Patients with Small Cell Lung Cancer (Summary Last Modified 05/90) | ||
| 08 87 3 | E.O.R.T.C. BRONCHIAL COOPERATIVE GROUP TENIPOSIDE FOR BRAIN METASTASES OF SMALL CELL LUNG CANCER. | ||
| 08 87 2 | PHASE II TRIAL OF ACNU WITH ADVANCED SMALL AND NON-SMALL CELL CARCINOMA OF THE LUNG. | ||
| 15 86 1 | EORTC STUDY GROUP ON QUALITY OF LIFE PROTOCOL 15861 DEVELOPMENT OF A CORE QUALITY OF LIFE QUESTIONNAIRE FOR USE IN CANCER CLINICAL TRIALS | ||
| 16 86 4E | Phase II Chemotherapy with Flavone Acetic Acid in Patients with Advanced non-Small Cell Lung Cancer (Summary Last Modified 07/88) | ||
| 07 86 1 | Phase II Randomized Study Comparing High-Dose CDDP/VP-16 with CBDCA/VP-16 in Patients with non-Small Cell Lung Cancer (Summary Last Modified 05/88) | ||
| 08 86 3 | CHEMOTHERAPY FOLLOWED BY SURGERY AND RADIOTHERAPY IN NSCLC PATIENTS WITH BIOPSY PROVEN N2 DISEASE. A PHASE II STUDY. | ||
| 16 85 1C | Phase II Trial of 5-Aza-2'-deoxycytidine in Patients with Advanced Squamous Cell Carcinoma, Adenocarcinoma, and Large Cell Carcinoma of the Lung | ||
| 08 86 4 | Phase II Chemotherapy with 4'-Epidoxorubicin in Patients with Mesothelioma | ||
| 08 86 1 | Adjuvant therapy in completely resected lung cancer. A randomized phase III study in operable non-small cell lung cancer (jointly with the EORTC Radiotherapy Cooperative Group) | ||
| 16 85 3A | Phase II trial of mitozolomide i.v. in patients with advanced small cell lung cancer | ||
| 08 86 2 | STANDARD COMBINATION CHEMOTHERAPY IN SMALL CELL LUNG CANCER, A PHASE II TRIAL. | ||
| 08 85 5 | Phase II Chemotherapy with Mitozolomide in Advanced Small and non-Small Cell Carcinoma of the Lung | ||
| 08 85 4 | PHASE II TRIAL OF 4'-EPIDoxorubicin IN ELDERLY OR UNFIT UNTREATED PATIENTS WITH ADVANCED SMALL CELL CARCINOMA OF THE LUNG. | ||
| 08 85 3 | Phase II trial of cisplatin-etoposide combination in recurrent or metastatic invasive thymoma | ||
| 04 85 1 | PHASE II TRIAL OF FOTEMUSTINE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA | ||
| 08 84 5 | ADJUVANT SURGERY AFTER INDUCTION CHEMOTHERAPY IN LIMITED SMALL CELL LUNG CANCER A RANDOMIZED PROSPECTIVE STUDY. | ||
| 07 85 3 | Randomized Study of Chemotherapy with VP-16/CACP/DAVA vs VP-16/DAVA as Induction Therapy for Small Cell Lung Cancer | ||
| 08 84 4 | Randomized phase III trial comparing radiotherapy + weekly cisplatin vs radiotherapy + daily cisplatin for inoperable non-small cell bronchogenic carcinoma (jointly with the EORTC Radiotherapy Cooperative Group) | ||
| 08 84 2 | COMBINATION CHEMOTHERAPY + SPLIT-DOSE RADIOTHERAPY, A RANDOMIZED PHASE II STUDY | ||
| 08 84 3 | Randomized Comparison of Adjuvant Postoperative Combination Chemotherapy with CED (CTX/VP-16/ADR) vs Resection Alone in Patients with Stage I Small Cell Carcinoma of the Lung | ||
| 08 82 5 | Induction vs induction plus maintenance chemotherapy in SCLC, a phase III trial | ||
| 1327 | Chemotherapy/afatinib continuation vs. chemotherapy alone in EGFR mut (+) NSCLC patients who progressed under 1st line EGFR tyrosine kinase inhibitor treatment. | ||
| 1335 | SPECTAlung: Screening Patients with thoracic tumors for Efficient Clinical Trial Access | ||
| 08 11 1 | A randomised, open-label phase III trial evaluating the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC | ||
| 22 11 3 | LungTech Stereotactic Body Radiotherapy (SBRT) of inoperable centrally located NSCLC: A phase II study in preparation for a randomized phase III trial | ||
|
| |||
Impressum Zuletzt geändert am 18.10.2014 18:20